RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement

Company has the funding, business plan, leadership and infrastructure to propel achievement of upcoming commercial and clinical milestonesMOUNTAIN VIEW, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced the closing of its previously announced, oversubscribed private placement of common st ...